Choice of therapy for psoriasis: inhibition of IL-23 p19 – data from clinical studies and real practice

The article presents the results of clinical studies and real practice of the effectiveness and safety of the use of a new genetically engineered biological drug Risankizumab. Skyrizi (risankizumab) is an innovative drug, it is a humanized monoclonal antibody – immunoglobulin class G1 (IgG1) – which specifcally inhibits the cytokine IL-23 by binding to its subunit p19. It is believed that cytokine IL-23, involved in inflammatory processes, is associated with a number of chronic immune-mediated diseases, including psoriasis. According to direct comparative randomized clinical trials, risankizumab is superior in effectiveness in the short term and, most importantly, in the long term most genetically engineered biologic drugs, including TNF-α inhibitors, secukinumab, ustekinumab. In the ultIMMa-1 and ultIMMa-2 studies, sPGA 0/1 and PASI 90 (p < 0.001) were achieved after 16 weeks of treatment with Skyrizi. After 16 weeks of treatment in both studies, the majority of patients achieved sPGA 0/1 (88% and 84%, respectively), and PASI 90 in both studies reached 75% of patients receiving Skyrizi. According to the LIMMitless open extended study, after completion of ultIMMa-1 and –2 (based on LOCF analysis), the proportion of patients receiving Skyrizi up to 2.5 years (136 weeks) withholding PASI 90 and PASI 100 was 87% and 63%, respectively. One of the potential advantages of IL-23 inhibitors is also the long-term maintenance of the achieved effect after treatment cessation. During patient management in the course of randomized controlled trials of phase 3, data were obtained on the high safety of the drug and the absence of signifcant risks in relation to serious infections, cardiovascular events, malignant neoplasms. The drug is effective in case of insuffcient response to adalimumab, ustekinumab, secukinumab. The article presents two clinical cases of the use of risankizumab in patients of different ages with severe psoriasis, with ineffciency or intolerance to systemic therapy, as well as in connection with the eluding effect of previously conducted treatment methods. PASI 90/100 was achieved in all patients. No adverse events were observed.

1. Langley R.G. Exploring new concepts in the successful management of psoriasis. J Eur Acad Dermatol Venereol. 2012 Mar; 26 Suppl 2: 1–2.

2. Potekaev N.N., Kruglova L.S. Psoriatic disease. Moscow. 2014. 264 р.

3. Bovenschen H.J., Vande Kerkhof P.C., van Erp P.E. et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A – Producing Cells and Are Found in Lesional Skin. Journal of Investigative Dermatology. 2011; 131: 1853–1860.

4. Nestle F., Kaplan D.H., Barcer J. Psoriasis. N Engl J Med. 2009; 361: 496–509.

5. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27: 485–517.

6. Psoriasis. National Clinical Guidelines. Dermatovenerology 2015: Skin disease. Sexually transmitted infections. 5th edition. Delovoy Express, 2016; 415–470 (in Russian).

7. SKYRIZI [Summary of Product Characteristics]. AbbVie Ltd. Available at: www.ema.europa.eu. 8. Gordon K., et al. Effcacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet. 2018 Aug 25; 392 (10148): 650–661.

8. Reich K., et al. Effcacy and Safety of Risankizumab Compared with Adalimumab in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Phase 3 IMMvent Trial. ePoster #P1813. European Academy of Dermatology and Venereology Congress. 2018.

9. Blauvelt A., et al. Risankizumab Effcacy / Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance [abstract P066]. Acta Derm Venereol. 2018; 98 (suppl 219): 30.

10. Leonardi C., Lebwohl M., Bachelez H., et al. Maintenance of response through 136 weeks of longterm continuous risankizumab treatment: an analysis of patients from UltIMMa-1 and UltIMMa-2. Presented at the Virtual Annual Meeting of the American Academy of Dermatology; June 12–14, 2020.

11. Langley, et al. Effcacy and Safety of Continuous Q12W Risankizumab versus Treatment Withdrawal: Results from the Phase 3 IMMhance Trial. Poster #10093. 2019 American Academy of Dermatology Annual Meeting. 2019.

12. Instructions for the medical use of the drug Skyrizi https://grls.rosminzdrav.ru/Default.aspx(accessed 28.10.2020).